Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Myriad Genetics (MYGN) over the last 4 years, with Q3 2025 value amounting to $119.5 million.

  • Myriad Genetics' Non-Current Debt rose 20641.03% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 20641.03%. This contributed to the annual value of $39.6 million for FY2024, which is 285.71% up from last year.
  • Per Myriad Genetics' latest filing, its Non-Current Debt stood at $119.5 million for Q3 2025, which was up 20641.03% from $59.3 million recorded in Q1 2025.
  • Myriad Genetics' 5-year Non-Current Debt high stood at $119.5 million for Q3 2025, and its period low was $38.4 million during Q2 2023.
  • In the last 3 years, Myriad Genetics' Non-Current Debt had a median value of $38.8 million in 2024 and averaged $50.0 million.
  • In the last 5 years, Myriad Genetics' Non-Current Debt soared by 104.17% in 2024 and then skyrocketed by 20641.03% in 2025.
  • Myriad Genetics' Non-Current Debt (Quarter) stood at $38.5 million in 2023, then grew by 2.86% to $39.6 million in 2024, then surged by 201.77% to $119.5 million in 2025.
  • Its Non-Current Debt was $119.5 million in Q3 2025, compared to $59.3 million in Q1 2025 and $39.6 million in Q4 2024.